Veru Inc (NASDAQ:VERU) insider Mitchell Shuster Steiner sold 20,000 shares of the stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $2.25, for a total value of $45,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Mitchell Shuster Steiner also recently made the following trade(s):
- On Wednesday, June 5th, Mitchell Shuster Steiner sold 20,000 shares of Veru stock. The shares were sold at an average price of $1.98, for a total value of $39,600.00.
- On Wednesday, May 1st, Mitchell Shuster Steiner sold 20,000 shares of Veru stock. The shares were sold at an average price of $1.43, for a total value of $28,600.00.
- On Wednesday, April 10th, Mitchell Shuster Steiner sold 7,686 shares of Veru stock. The shares were sold at an average price of $1.51, for a total value of $11,605.86.
Veru stock opened at $2.32 on Thursday. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.08. Veru Inc has a 12 month low of $1.18 and a 12 month high of $2.49. The company has a market cap of $144.42 million, a price-to-earnings ratio of -5.95 and a beta of 0.46. The business has a fifty day simple moving average of $2.04.
A number of research firms recently weighed in on VERU. Cantor Fitzgerald began coverage on Veru in a research report on Monday, July 1st. They set an “overweight” rating and a $6.00 price objective for the company. HC Wainwright raised their price objective on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Zacks Investment Research raised Hope Bancorp from a “sell” rating to a “hold” rating in a research report on Wednesday, April 17th. CIBC began coverage on Veru in a research report on Wednesday, March 20th. They set an “outperform” rating and a $5.00 price objective for the company. Finally, Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the company a “buy” rating in a research report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $4.67.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in Veru by 115.4% during the fourth quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after purchasing an additional 115,506 shares in the last quarter. Virtu Financial LLC purchased a new position in Veru during the first quarter valued at $95,000. Finally, BlackRock Inc. lifted its position in Veru by 9.3% during the fourth quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after purchasing an additional 10,956 shares in the last quarter. 8.85% of the stock is owned by institutional investors.
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Recommended Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.